GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca

cafead

Administrator
Staff member
  • cafead   Dec 03, 2018 at 10:42: AM
via GlaxoSmithKline on Monday agreed to pay $5.1 billion for Tesaro, becoming the latest firm to bet on a new type of cancer drug that has shown promise treating multiple tumor types but has yet to become a blockbuster seller.

article source
 

<